Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

Scott Kopetz, George J. Chang, Michael J. Overman, Cathy Eng, Daniel J. Sargent, David Larson, Axel F Grothey, Jean Nicolas Vauthey, David M. Nagorney, Robert R Mc Williams

Research output: Contribution to journalArticle

744 Citations (Scopus)

Abstract

Purpose: Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall survival of 8 to 12 months. With an increase in surgical resections of metastatic disease and development of new chemotherapies, indirect evidence suggests that outcomes for patients are improving in the general population, although the incremental gain has not yet been quantified. Methods: We performed a retrospective review of patients newly diagnosed with metastatic CRC treated at two academic centers from 1990 through 2006. Landmark analysis evaluated the association of diagnosis year and liver resection with overall survival. Additional survival analysis of the Surveillance Epidemiology and End Results (SEER) database evaluated a similar population from 1990 through 2005. Results: Two thousand four hundred seventy patients with metastatic CRC at diagnosis received their primary treatment at the two institutions during this time period. Median overall survival for those patients diagnosed from 1990 to 1997 was 14.2 months, which increased to 18.0, 18.6, and 29.3 months for patients diagnosed in 1998 to 2000, 2001 to 2003, and 2004 to 2006, respectively. Likewise, 5-year overall survival increased from 9.1% in the earliest time period to 19.2% in 2001 to 2003. Improved outcomes from 1998 to 2004 were a result of an increase in hepatic resection, which was performed in 20% of the patients. Improvements from 2004 to 2006 were temporally associated with increased utilization of new chemotherapeutics. In the SEER registry, overall survival for the 49,459 identified patients also increased in the most recent time period. Conclusion: Profound improvements in outcome in metastatic CRC seem to be associated with the sequential increase in the use of hepatic resection in selected patients (1998 to 2006) and advancements in medical therapy (2004 to 2006).

Original languageEnglish (US)
Pages (from-to)3677-3683
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number22
DOIs
StatePublished - Aug 1 2009

Fingerprint

Colorectal Neoplasms
Drug Therapy
Survival
Liver
Epidemiology
Leucovorin
Survival Analysis
Fluorouracil
Population
Registries
Therapeutics
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. / Kopetz, Scott; Chang, George J.; Overman, Michael J.; Eng, Cathy; Sargent, Daniel J.; Larson, David; Grothey, Axel F; Vauthey, Jean Nicolas; Nagorney, David M.; Mc Williams, Robert R.

In: Journal of Clinical Oncology, Vol. 27, No. 22, 01.08.2009, p. 3677-3683.

Research output: Contribution to journalArticle

Kopetz, Scott ; Chang, George J. ; Overman, Michael J. ; Eng, Cathy ; Sargent, Daniel J. ; Larson, David ; Grothey, Axel F ; Vauthey, Jean Nicolas ; Nagorney, David M. ; Mc Williams, Robert R. / Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 22. pp. 3677-3683.
@article{b57e9a682a814fb39bc9d77447f25144,
title = "Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy",
abstract = "Purpose: Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall survival of 8 to 12 months. With an increase in surgical resections of metastatic disease and development of new chemotherapies, indirect evidence suggests that outcomes for patients are improving in the general population, although the incremental gain has not yet been quantified. Methods: We performed a retrospective review of patients newly diagnosed with metastatic CRC treated at two academic centers from 1990 through 2006. Landmark analysis evaluated the association of diagnosis year and liver resection with overall survival. Additional survival analysis of the Surveillance Epidemiology and End Results (SEER) database evaluated a similar population from 1990 through 2005. Results: Two thousand four hundred seventy patients with metastatic CRC at diagnosis received their primary treatment at the two institutions during this time period. Median overall survival for those patients diagnosed from 1990 to 1997 was 14.2 months, which increased to 18.0, 18.6, and 29.3 months for patients diagnosed in 1998 to 2000, 2001 to 2003, and 2004 to 2006, respectively. Likewise, 5-year overall survival increased from 9.1{\%} in the earliest time period to 19.2{\%} in 2001 to 2003. Improved outcomes from 1998 to 2004 were a result of an increase in hepatic resection, which was performed in 20{\%} of the patients. Improvements from 2004 to 2006 were temporally associated with increased utilization of new chemotherapeutics. In the SEER registry, overall survival for the 49,459 identified patients also increased in the most recent time period. Conclusion: Profound improvements in outcome in metastatic CRC seem to be associated with the sequential increase in the use of hepatic resection in selected patients (1998 to 2006) and advancements in medical therapy (2004 to 2006).",
author = "Scott Kopetz and Chang, {George J.} and Overman, {Michael J.} and Cathy Eng and Sargent, {Daniel J.} and David Larson and Grothey, {Axel F} and Vauthey, {Jean Nicolas} and Nagorney, {David M.} and {Mc Williams}, {Robert R}",
year = "2009",
month = "8",
day = "1",
doi = "10.1200/JCO.2008.20.5278",
language = "English (US)",
volume = "27",
pages = "3677--3683",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

AU - Kopetz, Scott

AU - Chang, George J.

AU - Overman, Michael J.

AU - Eng, Cathy

AU - Sargent, Daniel J.

AU - Larson, David

AU - Grothey, Axel F

AU - Vauthey, Jean Nicolas

AU - Nagorney, David M.

AU - Mc Williams, Robert R

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Purpose: Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall survival of 8 to 12 months. With an increase in surgical resections of metastatic disease and development of new chemotherapies, indirect evidence suggests that outcomes for patients are improving in the general population, although the incremental gain has not yet been quantified. Methods: We performed a retrospective review of patients newly diagnosed with metastatic CRC treated at two academic centers from 1990 through 2006. Landmark analysis evaluated the association of diagnosis year and liver resection with overall survival. Additional survival analysis of the Surveillance Epidemiology and End Results (SEER) database evaluated a similar population from 1990 through 2005. Results: Two thousand four hundred seventy patients with metastatic CRC at diagnosis received their primary treatment at the two institutions during this time period. Median overall survival for those patients diagnosed from 1990 to 1997 was 14.2 months, which increased to 18.0, 18.6, and 29.3 months for patients diagnosed in 1998 to 2000, 2001 to 2003, and 2004 to 2006, respectively. Likewise, 5-year overall survival increased from 9.1% in the earliest time period to 19.2% in 2001 to 2003. Improved outcomes from 1998 to 2004 were a result of an increase in hepatic resection, which was performed in 20% of the patients. Improvements from 2004 to 2006 were temporally associated with increased utilization of new chemotherapeutics. In the SEER registry, overall survival for the 49,459 identified patients also increased in the most recent time period. Conclusion: Profound improvements in outcome in metastatic CRC seem to be associated with the sequential increase in the use of hepatic resection in selected patients (1998 to 2006) and advancements in medical therapy (2004 to 2006).

AB - Purpose: Fluorouracil/leucovorin as the sole therapy for metastatic colorectal cancer (CRC) provides an overall survival of 8 to 12 months. With an increase in surgical resections of metastatic disease and development of new chemotherapies, indirect evidence suggests that outcomes for patients are improving in the general population, although the incremental gain has not yet been quantified. Methods: We performed a retrospective review of patients newly diagnosed with metastatic CRC treated at two academic centers from 1990 through 2006. Landmark analysis evaluated the association of diagnosis year and liver resection with overall survival. Additional survival analysis of the Surveillance Epidemiology and End Results (SEER) database evaluated a similar population from 1990 through 2005. Results: Two thousand four hundred seventy patients with metastatic CRC at diagnosis received their primary treatment at the two institutions during this time period. Median overall survival for those patients diagnosed from 1990 to 1997 was 14.2 months, which increased to 18.0, 18.6, and 29.3 months for patients diagnosed in 1998 to 2000, 2001 to 2003, and 2004 to 2006, respectively. Likewise, 5-year overall survival increased from 9.1% in the earliest time period to 19.2% in 2001 to 2003. Improved outcomes from 1998 to 2004 were a result of an increase in hepatic resection, which was performed in 20% of the patients. Improvements from 2004 to 2006 were temporally associated with increased utilization of new chemotherapeutics. In the SEER registry, overall survival for the 49,459 identified patients also increased in the most recent time period. Conclusion: Profound improvements in outcome in metastatic CRC seem to be associated with the sequential increase in the use of hepatic resection in selected patients (1998 to 2006) and advancements in medical therapy (2004 to 2006).

UR - http://www.scopus.com/inward/record.url?scp=68949094312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949094312&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.20.5278

DO - 10.1200/JCO.2008.20.5278

M3 - Article

C2 - 19470929

AN - SCOPUS:68949094312

VL - 27

SP - 3677

EP - 3683

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -